Table 5 HIV, HBsAg, anti-HCV, HCV PCR prevalence and HCV viraemic rate among participants (n = 3439)
|  | SWs (n = 1528) | MSM (n = 746) | PWUD/ID (n = 1165) | TOTAL | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | CT | PE | Mthatha | DBN | PMB | CT | JHB | PTA | CT | DBN | PTA | Â |
N | 384 | 248 | 248 | 399 | 249 | 250 | 250 | 246 | 367 | 398 | 400 | 3439 |
HIV + ve | 69 (18%) | 90 (38%) | 133 (56%) | 220 (55%) | 199 (80%) | 101 (40%) | 122 (49%) | 97 (41%) | 22 (6%) | 65 (16%) | 140 (35%) | 1258 (37%) |
HBsAg + ve | 13 (3%) | 8 (3%) | 10 (4%) | 17 (4%) | 13 (5%) | 9 (4%) | 10 (4%) | 6 (2%) | 20 (5%) | 15 (4%) | 20 (5%) | 141 (4%) |
Anti-HCV + ve ELISA | 1 (< 1%) | 0 | 0 | 0 | 0 | 16 (6%) | 3 (1%) | 1 (< 1%) | 136 (37%) | 113 (28%) | 288 (72%) | 558 (16%) |
HCV viral load detectable | 0 | 0 | 0 | 0 | 0 | 15 (6%) | 2 (1%) | 0 | 102 (28%) | 90 (23%) | 227 (57%) | 436 (13%) |
HCV viraemic rate (among anti_HCV + ve) | 0 | 0 | 0 | 0 | 0 | 94% | 67% | 0 | 75% | 80% | 79% | 78% |
Anti-HCV-HIV co-infection | 0 | 0 | 0 | 0 | 0 | 6 (2%) | 3 (1%) | 1 (< 1%) | 10 (3%) | 25 (6%) | 113 (28%) | 158 (5%) |
Anti-HCV prevalence among HIV + ve participants | 0 | 0 | 0 | 0 | 0 | 6 (6%) | 3 (2%) | 1 (1%) | 10 (45%) | 25 (38%) | 113 (81%) | 158 (13%) |
Anti-HCV-HBV co-infection | 0 | 0 | 0 | 0 | 0 | 1 (< 1%) | 0 | 0 | 5 (1%) | 5 (1%) | 17 (4%) | 28 (< 1%) |
HIV-HBsAg co-infection | 5 (1%) | 3 (1%) | 9 (4%) | 13 (3%) | 12 (5%) | 5 (2%) | 7 (3%) | 3 (1%) | 3 (1%) | 6 (2%) | 9 (2%) | 75 (2%) |
HIV-anti-HCV-HBV co-infection | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (1%) | 8 (2%) | 10 (< 1%) |